Ignite Creation Date:
2024-05-06 @ 9:34 AM
Last Modification Date:
2024-10-26 @ 12:16 PM
Study NCT ID:
NCT03013543
Status:
COMPLETED
Last Update Posted:
2023-08-18
First Post:
2017-01-03
Brief Title:
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Sponsor:
Rhythm Pharmaceuticals Inc
Organization:
Rhythm Pharmaceuticals Inc
Study Overview
Official Title:
Setmelanotide RM-493 Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study was to determine the effect of setmelanotide RM-493 on weight hunger assessments and other factors in participants with rare genetic disorders of obesity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2017-000387-14 | EUDRACT_NUMBER | None | None |